179 related articles for article (PubMed ID: 18199708)
1. Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
Cai Q; Kataoka N; Li C; Wen W; Smith JR; Gao YT; Shu XO; Zheng W
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):27-32. PubMed ID: 18199708
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
Olson JE; Ingle JN; Ma CX; Pelleymounter LL; Schaid DJ; Pankratz VS; Vierkant RA; Fredericksen ZS; Wu Y; Couch FJ; Vachon CM; Sellers TA; Weinshilboum RM
Breast Cancer Res Treat; 2007 Apr; 102(2):237-47. PubMed ID: 17004113
[TBL] [Abstract][Full Text] [Related]
6. Interaction between CYP19A1 polymorphisms and body mass index in the risk of endometrial cancer in postmenopausal Japanese women.
Hosono S; Matsuo K; Ito H; Watanabe M; Hirose K; Nakanishi T; Tajima K; Tanaka H
Asian Pac J Cancer Prev; 2011; 12(10):2747-52. PubMed ID: 22320986
[TBL] [Abstract][Full Text] [Related]
7. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
Chen C; Sakoda LC; Doherty JA; Loomis MM; Fish S; Ray RM; Lin MG; Fan W; Zhao LP; Gao DL; Stalsberg H; Feng Z; Thomas DB
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3457-66. PubMed ID: 19064562
[TBL] [Abstract][Full Text] [Related]
9. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Kopp TI; Jensen DM; Ravn-Haren G; Cohen A; Sommer HM; Dragsted LO; Tjonneland A; Hougaard DM; Vogel U
BMC Cancer; 2016 Apr; 16():283. PubMed ID: 27102200
[TBL] [Abstract][Full Text] [Related]
10. CYP19 (aromatase) haplotypes and endometrial cancer risk.
Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I
Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
12. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
Talbott KE; Gammon MD; Kibriya MG; Chen Y; Teitelbaum SL; Long CM; Gurvich I; Santella RM; Ahsan H
Breast Cancer Res Treat; 2008 Oct; 111(3):481-7. PubMed ID: 17975727
[TBL] [Abstract][Full Text] [Related]
13. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population.
Lee SJ; Kim WY; Choi JY; Lee SS; Shin JG
J Hum Genet; 2010 Mar; 55(3):189-93. PubMed ID: 20186154
[TBL] [Abstract][Full Text] [Related]
14. Catechol-O-methyltransferase haplotypes and breast cancer among women on Long Island, New York.
Gaudet MM; Bensen JT; Schroeder J; Olshan AF; Terry MB; Eng SM; Teitelbaum SL; Britton JA; Lehman TA; Neugut AI; Ambrosone CB; Santella RM; Gammon MD
Breast Cancer Res Treat; 2006 Sep; 99(2):235-40. PubMed ID: 16596327
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.
Gaudet MM; Chanock S; Lissowska J; Berndt SI; Peplonska B; Brinton LA; Welch R; Yeager M; Bardin-Mikolajczak A; Garcia-Closas M
Cancer Res; 2006 Oct; 66(19):9781-5. PubMed ID: 17018638
[TBL] [Abstract][Full Text] [Related]
16. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
[TBL] [Abstract][Full Text] [Related]
17. Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Friesenhengst A; Pribitzer-Winner T; Miedl H; Pröstling K; Schreiber M
Horm Cancer; 2018 Apr; 9(2):128-138. PubMed ID: 29363090
[TBL] [Abstract][Full Text] [Related]
18. Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study.
Tamimi RM; Hankinson SE; Spiegelman D; Kraft P; Colditz GA; Hunter DJ
Breast Cancer Res; 2004; 6(4):R416-22. PubMed ID: 15217510
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
[TBL] [Abstract][Full Text] [Related]
20. [Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
Du ZG; Wang LY; Zhou Y; Wan HY; Liang FQ; Lyu Q
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):827-832. PubMed ID: 30107717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
